Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,473 across all filing types
Latest filing 2021-05-27 AGM Information
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-election of Retiring Directors and Notice of Annual General Meeting
AGM Information Classification · 95% confidence The document is a circular from Ascletis Pharma Inc. regarding proposals for general mandates to issue and repurchase shares, re-election of retiring directors, and notice of the Annual General Meeting (AGM). It includes detailed information about the AGM agenda, explanatory statements, and director nomination procedures. The presence of a notice of AGM and related proposals indicates this document is intended to inform shareholders about the upcoming AGM and related voting matters. It is not a full annual report, earnings release, or financial statement, but rather a communication related to the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-05-27 English
VOLUNTARY ANNOUNCEMENT - GANNEX RECEIVED CHINA IND APPROVAL OF ITS FXR AGONIST ASC42 FOR NASH INDICATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the approval of an Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for a drug candidate ASC42. It includes information about clinical trial approvals, expected trial phases, and regulatory designations such as Fast Track by the U.S. FDA. The document is relatively short (2556 characters) and does not contain financial statements or detailed financial data. It is an update on regulatory and clinical development progress rather than a financial report or formal filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a report publication announcement since it contains substantive content about regulatory approval. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-05-27 English
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF ASC40 COMBINED WITH BEVACIZUMAB TO TREAT PATIENTS WITH RECURRENT GLIOBLASTOMA ACCEPTED BY CHINA NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the acceptance of a clinical trial application by the China National Medical Products Administration (NMPA). It discusses clinical trial data and regulatory acceptance but does not contain financial statements, management changes, voting results, or other report types. The document is relatively short (2960 characters) and serves as a regulatory update or announcement rather than a full report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require substantive financial data. It is not a certification or officer attestation. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-05-25 English
VOLUNTARY ANNOUNCEMENT - POSITIVE PHASE IIA HBV RESULTS ON SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding positive Phase IIa clinical trial results for a drug candidate (ASC22). It contains no financial statements or detailed financial data, nor does it present a full report or regulatory filing. The document is relatively short (3911 characters) and serves as an update on clinical trial progress and strategic partnership information. It is not an earnings release, annual report, or any form of financial report. It is also not a regulatory filing or certification. The content is primarily an announcement of clinical trial results and related business updates, which fits best under the category of a general regulatory announcement or miscellaneous company update. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2021-05-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/4/2021 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and confirmations related to securities issuance, with no financial performance data, earnings, or management discussion. This type of document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange, fitting the category of Regulatory Filings (RNS). It is not a full financial report, earnings release, or capital/financing update but a compliance report on share capital movements.
2021-05-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 April 2021
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/04/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in the company's share capital structure during a specific month. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory filing reporting share capital movements, typical for compliance with exchange rules. It is not an annual or interim report, earnings release, or management report. It is not a proxy, AGM material, or voting result announcement. Given the detailed nature of share capital movements, it fits best under the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains substantive data on share capital changes, not just an announcement or certification. Therefore, the classification is SHA with high confidence.
2021-05-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.